Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

The human monoclonal antibody opicinumab (BIIB033, anti-LINGO-1) has shown remyelinating activity in preclinical studies. We therefore assessed the safety and tolerability, and efficacy of opicinumab given soon after a first acute optic neuritis episode. This randomised, double-blind, placebo-contro...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Lancet neurology Ročník 16; číslo 3; s. 189 - 199
Hlavní autori:	Cadavid, Diego, Balcer, Laura, Galetta, Steven, Aktas, Orhan, Ziemssen, Tjalf, Vanopdenbosch, Ludo, Frederiksen, Jette, Skeen, Mark, Jaffe, Glenn J, Butzkueven, Helmut, Ziemssen, Focke, Massacesi, Luca, Chai, Yi, Xu, Lei, Freeman, Stefanie
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Ltd 01.03.2017 Elsevier Limited
Predmet:	Acute Disease Adolescent Adult Antibodies, Monoclonal - therapeutic use Clinical trials Double-Blind Method Electroencephalography Evoked Potentials, Visual - drug effects Female Humans Immunoglobulins Immunologic Factors - therapeutic use International Cooperation Male Membrane Proteins - immunology Middle Aged Multiple sclerosis Nerve Tissue Proteins - immunology Neurology Optic Neuritis - drug therapy PubMed - statistics & numerical data Retrospective Studies Studies Treatment Outcome Young Adult
ISSN:	1474-4422, 1474-4465, 1474-4465
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!